[Bio CEO Interview] RudaCure CEO Yongho Kim pursues active joint research with Hanlim Pharmaceutical, including RCI001 Phase 1 clinical trials, to overcome the limitations of bio-ventures
http://www.medigatenews.com/news/2535905009
"Securing diverse pipelines beyond dry eye disease to establish ourselves as a company that overcomes bio-venture limitations"
RudaCure's R&D pipeline — including RCI001 as well as pain treatment RCI002, atopic dermatitis treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related macular degeneration treatment RCI005 — consists entirely of treatments for sensory disorders related to quality of life.
RCI002 is planned to undergo preclinical trials this year, with DS/DP production in the following year, and Phase 1 clinical trials in 2023. Currently, in vitro efficacy studies are underway.